Large pharmaceutical companies (Multinational Pharmaceutical Companies or MPCs) have struggled in recent years with the rapidly accelerating costs of drug-discovery research and development. These costs continue to rise while resulting in fewer drug leads. Several industries have realized...

Venture capital investment performance data and performance attribution are not typically published. Venture investors articulate (and sell to LPs) conflicting strategies; the popular business literature and culture is rife with rapidly changing beliefs about the relative attractiveness of...